See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Natural Disasters
Baseball
Donald Trump
Social Media
Trade War
Artificial Intelligence
Education
Nintendo
Stock Markets
Senate
Published • loading... • Updated

Use High efficacy Agents as early as possible is what you want

Summary by Multiple Sclerosis Research Blog
Duh. This is natalizumab as first line use verses later use and it works better first line use…ABIT of a NSS moment. ProfK is starting natalizumab first linen in ATTACK-MS. Avila RL, Croteau …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Multiple Sclerosis Research BlogMultiple Sclerosis Research Blog

Use High efficacy Agents as early as possible is what you want

Duh. This is natalizumab as first line use verses later use and it works better first line use…ABIT of a NSS moment. ProfK is starting natalizumab first linen in ATTACK-MS. Avila RL, Croteau …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Multiple Sclerosis Research Blog broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal